P3‐304: MODELS OF PATIENT ENGAGEMENT IN ALZHEIMER'S DISEASE (MOPEAD): A EUROPEAN MULTINATIONAL PROJECT TO DEVELOP AND TEST INNOVATIVE PATIENT ENGAGEMENT STRATEGIES

Numerous health economic studies have shown that early diagnosis of Alzheimer's disease (AD) leads to significant economic and social benefits. It has been also suggested that an earlier intervention results in a higher probability of success when testing new drugs. Despite this evidence, the diagnosis of AD is still made at late stages in Europe, and even a proportion of cases remain undiagnosed. In this context, raising awareness of the importance of early diagnosis among the general population and health care professionals is of great importance. The development of new and more efficient patient engagement (PE) strategies should be a priority as well. MOPEAD aims to test 4 different PE strategies called Runs, which allow us to conduct a pre-screening procedure to identify individuals at risk of cognitive impairment. Run 1 is a prescreening procedure based on online tools. Run 2 is an Open House Initiative in which individuals are welcome to test their cognition in a memory clinic without a physician's referral. Runs 3 and 4 are campaigns to detect cognitive impairment in the primary care setting and diabetes specialist office respectively. The 4 Runs will be conducted simultaneously in 5 European countries (Spain, Netherlands, Sweden, Germany and Slovenia). Each Run aims to identify individuals at risk who, consequently, will be referred to a memory clinic to undergo a full diagnostic examination enhanced with biomarkers. The data will be analyzed using a big data approach in order to identify the most cost-effective PE strategies. MOPEAD will be conducted by a multinational consortium, and involves academic partners, IT experts, the pharmaceutical industry and patient associations among others (see supplementary table). MOPEAD is funded by the Innovative Medicines Initiative (IMI) (GA 115985-MOPEAD-H2020-JTI- IMI2015-05). The grant agreement was signed in October 2016 and the time frame for the completion of the project is 33 months. Recruitment is expected to begin in the spring of 2018. MOPEAD is an innovative project based on a synergy of several private and public institutions with different expertise profiles which aim to promote a change in the paradigm of early AD diagnosis and PE strategies.